STRATA Skin Sciences, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization
Impairment of goodwill
Amortization of operating lease right-of-use assets
Amortization of deferred financing costs and debt discount
Provision for credit losses
Stock-based compensation expense
Loss on debt extinguishment
Loss on disposal of property and equipment
Settlement gains
Inventory write-off
Deferred income taxes
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities
Deferred revenues
Operating lease liabilities
Net cash (used in) provided by operating activities
Cash flows from investing activities:
Purchase of property and equipment
Cash paid in connection with TheraClear asset acquisition
TheraClear Corporation
RA Medical Systems, Inc.
Total cash paid in connection with TheraClear asset acquisition
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from exercise of stock options
Proceeds from long-term debt
Payment of deferred financing costs
Repayment of note payable
Repayments of long-term debt
Payment of contingent consideration
Sale of common stock, net of offering costs
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year

Supplemental disclosure of cash flow information:
Cash paid during the year for interest
Cash paid during the year for income taxes
Supplemental schedule of non-cash operating, investing and financing activities:
Modification of common stock warrants
Transfer of property and equipment to inventories
Issuance of common stock warrants in connection with Senior Term Facility
Assumed deferred revenues in connection with asset acquisition
Change in intangible assets and fair value of contingent consideration
Accrued equity issuance costs included in accounts payable
Write-off of contingent consideration to settlement gains
Write-off of intangible assets to settlement gains
Accrued exit fee recorded as debt discount
Accrued payment of contingent consideration
Inventories acquired in connection with TheraClear asset acquisition
Intangible assets acquired in connection with TheraClear asset acquisition
Contingent consideration issued in connection with TheraClear asset acquisition
Contingent consideration issued in connection with TheraClear asset
Common stock issued in connection with TheraClear asset acquisition
Change in operating lease right-of-use assets and liabilities due to new and amended leases
Operating lease right-of-use assets obtained in exchange for operating lease liabilities

Comments